228 related articles for article (PubMed ID: 29136527)
1. Targeting splicing abnormalities in cancer.
Agrawal AA; Yu L; Smith PG; Buonamici S
Curr Opin Genet Dev; 2018 Feb; 48():67-74. PubMed ID: 29136527
[TBL] [Abstract][Full Text] [Related]
2. Aberrant RNA splicing and therapeutic opportunities in cancers.
Yamauchi H; Nishimura K; Yoshimi A
Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targeting of RNA Splicing in Cancer.
Bonner EA; Lee SC
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
[TBL] [Abstract][Full Text] [Related]
4. Targeting splicing factors for cancer therapy.
Bashari A; Siegfried Z; Karni R
RNA; 2023 Apr; 29(4):506-515. PubMed ID: 36697261
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of splicing in cancer.
Lee SC; Abdel-Wahab O
Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132
[TBL] [Abstract][Full Text] [Related]
6. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
7. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
[TBL] [Abstract][Full Text] [Related]
8. Emerging roles of spliceosome in cancer and immunity.
Yang H; Beutler B; Zhang D
Protein Cell; 2022 Aug; 13(8):559-579. PubMed ID: 34196950
[TBL] [Abstract][Full Text] [Related]
9. Spliceosomal factor mutations and mis-splicing in MDS.
Hershberger CE; Daniels NJ; Padgett RA
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
[TBL] [Abstract][Full Text] [Related]
10. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
11. RNA Splicing and Cancer.
Wang E; Aifantis I
Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
[TBL] [Abstract][Full Text] [Related]
12. Splicing-factor alterations in cancers.
Anczuków O; Krainer AR
RNA; 2016 Sep; 22(9):1285-301. PubMed ID: 27530828
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.
Lin JC
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283381
[TBL] [Abstract][Full Text] [Related]
14. Non-canonical functions of spliceosome components in cancer progression.
Ivanova OM; Anufrieva KS; Kazakova AN; Malyants IK; Shnaider PV; Lukina MM; Shender VO
Cell Death Dis; 2023 Feb; 14(2):77. PubMed ID: 36732501
[TBL] [Abstract][Full Text] [Related]
15. Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1).
Chung FF; Tan PF; Raja VJ; Tan BS; Lim KH; Kam TS; Hii LW; Tan SH; See SJ; Tan YF; Wong LZ; Yam WK; Mai CW; Bradshaw TD; Leong CO
Sci Rep; 2017 Feb; 7():42504. PubMed ID: 28198434
[TBL] [Abstract][Full Text] [Related]
16. Alternative splicing in Alzheimer's disease.
Biamonti G; Amato A; Belloni E; Di Matteo A; Infantino L; Pradella D; Ghigna C
Aging Clin Exp Res; 2021 Apr; 33(4):747-758. PubMed ID: 31583531
[TBL] [Abstract][Full Text] [Related]
17. Identification of a small molecule splicing inhibitor targeting UHM domains.
Kobayashi A; Clément MJ; Craveur P; El Hage K; Salone JM; Bollot G; Pastré D; Maucuer A
FEBS J; 2022 Feb; 289(3):682-698. PubMed ID: 34520118
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations.
Urrutia S; Li Z; Almanza E; Bataller A; Kanagal-Shamanna R; Senapati J; Sasaki K; Chien K; Montalban-Bravo G; DiNardo C; Borthakur G; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Leukemia; 2023 Jun; 37(6):1397-1400. PubMed ID: 37185307
[No Abstract] [Full Text] [Related]
19. Insights from structures of cancer-relevant pre-mRNA splicing factors.
Kielkopf CL
Curr Opin Genet Dev; 2018 Feb; 48():57-66. PubMed ID: 29128695
[TBL] [Abstract][Full Text] [Related]
20. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.
Pilch B; Allemand E; Facompré M; Bailly C; Riou JF; Soret J; Tazi J
Cancer Res; 2001 Sep; 61(18):6876-84. PubMed ID: 11559564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
